Loestrin

DRUG5 trials

Sponsors

Eisai Inc., Bristol-Myers Squibb, ViiV Healthcare

Conditions

HIV InfectionsHealthy Female VolunteersHealthy ParticipantsHealthy Subjects

Phase 1

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

CompletedNCT03451110

Eisai Inc.Healthy Subjects

Start: 2018-02-05End: 2018-03-23Updated: 2018-09-06

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

CompletedNCT04016753

Bristol-Myers SquibbHealthy Participants

Start: 2019-08-05End: 2020-02-21Updated: 2022-05-31

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

CompletedNCT05579574

Bristol-Myers SquibbHealthy Participants

Start: 2022-10-21End: 2023-06-01Updated: 2023-08-18

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

CompletedNCT05891262

Bristol-Myers SquibbHealthy Female Volunteers

Start: 2023-06-06End: 2023-08-25Updated: 2023-09-25

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

CompletedNCT06310616

ViiV HealthcareHIV Infections

Start: 2024-03-06End: 2024-08-15Updated: 2024-12-10